Bayer registers bioavailability study comparing two elinzanetant formulations
Phase 1 crossover trial in 100 healthy women will compare absorption of two oral elinzanetant forms used for hot flush symptoms.
Bayer's week includes one newly registered early-phase pharmacokinetics study.
- Elinzanetant (BAY 3427080), Phase 1, vasomotor symptoms: Registered a crossover trial comparing two oral formulations. The study aims to find out whether a new tablet form of elinzanetant is absorbed and processed by the body of healthy women in a similar way than an existing capsule form.1 The trial is recruiting, with about 100 healthy women aged 18 to 651 enrolling, and primary completion is estimated for 2027-01-221.
Written by readthrough’s AI from the linked primary sources and fact-checked against them automatically before publishing. Not investment advice.